A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs RG 125 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 23 Oct 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.
- 23 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2018.
- 23 Oct 2017 Status changed to active, no longer recruiting.